Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation

Vaccine

Volumn 30, Issue 48, 2012, Pages 6864-6870

  Lagler, Heimo ^a   Tobudic, Selma ^a   Ramharter, Michael ^a,b   Elandt, Katarzyna ^a   Sperr, Wolfgang R ^a   Redlberger Fritz, Monika ^a   Popow Kraupp, Theresia ^a   Jäger, Ulrich ^a   Zielinski, Christoph C ^a   Burgmann, Heinz ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Acceptability; Adjuvant free H1N1 vaccine; Cancer patients; Chemotherapy; Immunogenicity

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CHLORAMBUCIL; CYTARABINE; CYTOTOXIC AGENT; INFLUENZA VACCINE; RITUXIMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTIBODY TITER; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER THERAPY; CHRONIC LEUKEMIA; CONTROLLED STUDY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEOMETRY; HEMAGGLUTINATION INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROSTATE CANCER; SEROCONVERSION; SOLID TUMOR; VACCINATION; VERO CELL; VIRION;

ADULT; AGED; ANTIBODIES, VIRAL; ANTINEOPLASTIC AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEOPLASMS; PATIENT ACCEPTANCE OF HEALTH CARE;

EID: 84868208033     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.005     Document Type: Article

References (45)

1. Kempe A., Hall C.B., MacDonald N.E., Foye H.R., Woodin K.A., Cohen H.J., et al. Influenza in children with cancer. J Pediatr 1989, 115:33-39.
2. Yousuf H.M., Englund J., Couch R., Rolston K., Luna M., Goodrich J., et al. Influenza among hospitalized adults with leukemia. Clin Infect Dis 1997, 24:1095-1099.
3. Elting L.S., Whimbey E., Lo W., Couch R., Andreeff M., Bodey G.P. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 1995, 3:198-202.
4. Lo W., Whimbey E., Elting L., Couch R., Cabanillas F., Bodey G. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis 1993, 12:778-782.
5. Rapezzi D., Sticchi L., Racchi O., Mangerini R., Ferraris A.M., Gaetani G.F. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. Eur J Haematol 2003, 70:225-230.
6. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9:493-504.
7. Feldman S., Webster R.G., Sugg M. Influenza in children and young adults with cancer: 20 cases. Cancer 1977, 39:350-353.
8. Avritscher E.B., Cooksley C.D., Geraci J.M., Bekele B.N., Cantor S.B., Rolston K.V., et al. Cost-effectiveness of influenza vaccination in working-age cancer patients. Cancer 2007, 109:2357-2364.
9. Arrowood J.R., Hayney M.S. Immunization recommendations for adults with cancer. Ann Pharmacother 2002, 36:1219-1229.
10. Melcher L. Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy. Clin Oncol (R Coll Radiol) 2005, 17:12-15.
11. Fiore A.E., Shay D.K., Haber P., Iskander J.K., Uyeki T.M., Mootrey G., et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007, 56:1-54.
12. Morse D., Pickering L., Baker C., Beck R., Chilton L., Cieslak P., et al. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009, 58:1-8.
13. European Medicines Agency. Assessment Report for Celvapan. Common Name: Pandemic influenza vaccine (H1N1) (whole virion, Vero cell derived, inactivated) A/California/07/2009 (H1N1)v. London 01 October 2009.Available from: [accessed 10.07.12]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000982/WC500022669.pdf.
14. Girard M.P., Katz J., Pervikov Y., Palkonyay L., Kieny M.P. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. Vaccine 2010, 28:6811-6820.
15. Barrett P.N., Berezuk G., Fritsch S., Aichinger G., Hart M.K., El-Amin W., et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011, 377:751-759.
16. Coudeville L., Bailleux F., Riche B., Megas F., Andre P., Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med Res Methodol 2010, 10:18.
17. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972, 70:767-777.
18. Committee for Human Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). London 1997. Available from: [accessed 10.02.12]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
19. Johansen K., Nicoll A., Ciancio B.C., Kramarz P. Pandemic influenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill 2009, 14:19361.
20. Virologische Arbeitsmethoden, Band II (Serologie) 1977, 207-291. Gustav Fischer Verlag, Stuttgart. A. Mayr, B.A. Bachmann, B. Bibrack, G. Wittmann (Eds.).
21. Lagler H., Wenisch J.M., Tobudic S., Gualdoni G.A., Rodler S., Rasoul-Rockenschaub S., et al. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination. Vaccine 2011, 29:6888-6893.
22. Schmid D, Lachner P, Allerberger F. Report of the National Reference Centre for Influenza Epidemiology 2010/2011 of the Austrian Agency for Health and Food Safety (AGES). Available from: [accessed 15.08.12]. http://www.ages.at/ages/gesundheit/mensch/influenza/das-influenza-surveillance-system.
23. Müller M. [On the press coverage on the Austrian allocation of vaccine against the pandemic influenza A/H1N1] Article in German. Wien Klin Wochenschr 2009, 121:663-664.
24. Nicholson K.G., Abrams K.R., Batham S., Clark T.W., Hoschler K., Lim W.S., et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011, 11:91-101.
25. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340:c2649.
26. Schwarzinger M., Flicoteaux R., Cortarenoda S., Obadia Y., Moatti J.P. Low acceptability of A/H1N1 pandemic vaccination in French adult population: did public health policy fuel public dissonance?. PLoS One 2010, 5:e10199.
27. Loulergue P., Mir O., Alexandre J., Ropert S., Goldwasser F., Launay O. Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol 2008, 19(9):1658. [letter].
28. Ring A., Marx G., Steer C., Prendiville J., Ellis P. Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy. Int J Clin Pract 2003, 57:542-543.
29. Yee S.S., Dutta P.R., Solin L.J., Vapiwala N., Kao G.D. Lack of compliance with national vaccination guidelines in oncology patients receiving radiation therapy. J Support Oncol 2010, 8:28-34.
30. Hodges G.R., Davis J.W., Lewis H.D.J., Whittier F.C.J., Siegel C.D., Chin T.D., et al. Response to influenza A vaccine among high-risk patients. South Med J 1979, 72:29-32.
31. Stiver H.G., Weinerman B.H. Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients. Can Med Assoc J 1978, 119. 733,-5, 738.
32. Shildt R.A., Luedke D.W., Kasai G., El-Beheri S., Laham M.N. Antibody response to influenza immunization in adult patients with malignant disease. Cancer 1979, 44:1629-1635.
33. Miraglia J.L., Abdala E., Hoff P.M., Luiz A.M., Oliveira D.S., Saad C.G., et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS One 2011, 6:e27214.
34. Miller E., Hoschler K., Hardelid P., Stanford E., Andrews N., Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010, 375:1100-1108.
35. Pollyea D.A., Brown J.M., Horning S.J. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010, 28:2481-2490.
36. Anderson H., Petrie K., Berrisford C., Charlett A., Thatcher N., Zambon M. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer 1999, 80:219-220.
37. Brydak L.B., Guzy J., Starzyk J., Machala M., Gozdz S.S. Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 2001, 9:65-68.
38. Meerveld-Eggink A., de Weerdt O., van der Velden A.M., Los M., van der Velden A.W., Stouthard J.M., et al. Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol 2011, 22:2031-2035.
39. Rousseau B., Loulergue P., Mir O., Krivine A., Kotti S., Viel E., et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol 2012, 23:450-457.
40. Nicholson K.G., Abrams K.R., Batham S., Clark T.W., Hoschler K., Lim W.S., et al. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart. Health Technol Assess 2010, 14:193-334.
41. Dikow R., Eckerle I., Ksoll-Rudek D., Hampel H., Schwenger V., Zeier M., et al. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis 2011, 57:716-723.
42. Meyer S., Adam M., Schweiger B., Ilchmann C., Eulenburg C., Sattinger E., et al. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients. Transplantation 2011, 91:1031-1035.
43. Xu Y., Methuku N., Coimbatore P., Fitzgerald T., Huang Y., Xiao Y.Y., et al. Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer. Oncologist 2012, 17:125-134.
44. de Lavallade H., Garland P., Sekine T., Hoschler K., Marin D., Stringaris K., et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2011, 96:307-314.
45. Mackay H.J., McGee J., Villa D., Gubbay J.B., Tinker L.M., Shi L., et al. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol 2011, 50:212-216.